Industry Trends

A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation.

Webinar Date/Time: Wednesday, March 6th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Under the agreement, Bristol Myers Squibb obtains Mirati’s entire portfolio, including Krazati (adagrasib) for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.

Sun Pharmaceutical Industries will purchase Taro's outstanding shares for $43 each, which will total $348 million.

Webinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST

Experts weigh in on recent trends regarding weight loss medication and how they expect those trends to evolve in the coming year.

Generative artificial intelligence, key new product launches, and the evolution of the go-to-market model are among key trends to watch in the year ahead.

Investors may be attracted to precision medicine and gene therapy in the coming year due to a variety of reasons, including the treatments’ abilities to produce exact responses.

Merck has acquired Harpoon Therapeutics with its clinical stage T-cell engager, whereas Johnson & Johnson acquired Ambrx Biopharma with its expertise in next generation antibody drug conjugates and targeted oncologic therapies.

Tina Fresta, BA, MPH is the Strategic Solutions Senior Manager at epocrates, keeps a close eye on the pharmaceutical and bio science industry shifts, leveraging those insights to inform both our partners and our company of the most strategic approach to reach business goals.

Company cites potential safety risks for patients who ignore the intended indication of Mounjaro and Zepbound.

Webinar Date/Time: Tue, Jan 30, 2024 10:00 AM EST | 9:00 AM CT | 3:00 PM GMT | 4:00 PM CET

Practical recommendations for a path forward for both biopharma C-Suites and their employees.

Merger agreement includes the Gracell FasTCAR platform, which could significantly improve the efficacy of CAR T-cell therapies.

In the coming year, efficiency and automation will take center stage to maximize constrained resources but balancing sensible financial management with strategic investments will be vital.

CDC data show hospitalizations among all age groups spiked by 200% for influenza, 51% for COVID-19, and 60% for respiratory syncytial virus over the past four weeks, emphasizing the need for improved outreach efforts among at-risk populations.

JAMA Network study evaluates current attitudes toward individuals with acne with a call for pharma companies to focus efforts on helping to overcome these stigmas.

In-depth study outlines the top five reasons biopharma products miss launch forecasts.

Pfizer Inc. expects to close its $43 billion acquisition of Seagen Inc., on December 14, 2023.

The deal includes Icosavax’s lead investigational candidate, IVX-A12, a potential first-in-class vaccine being developed for both respiratory syncytial virus and human metapneumovirus.

Arthritis, asthma, cancer, cardiovascular diseases, chronic kidney disease, COPD, depression, and diabetes reach the highest recorded levels since the America’s Health Rankings Annual Report began tracking them in 1990.

An overview of the nine biggest developments to expect across the healthcare industry in the year ahead.

Jennifer Breheny Wallace, award-winning journalist and author, notes that C-Suite leaders should understand the financial risks of not taking action to address workplace burnout in 2024.

Roche announces definitive merger agreement to acquire Carmot Therapeutics, Inc., which has an R&D portfolio that includes clinical stage subcutaneous and oral incretins for the treatment of patients with obesity, both with and without diabetes.

The CDC’s Morbidity and Mortality Weekly Report show pediatric influenza hospitalization rates returned to levels that preceded the COVID-19 pandemic.

An overview of what biopharma C-Suites and their boards should consider when engaging with government and business leaders from China, the world’s second largest economy.

Webinar Date/Time: Tue, Dec 12, 2023 10:00 AM EST | 9:00 AM CT | 3:00 PM GMT | 4:00 PM CET

Nevertheless, it’s time to reassess how to leverage for greatest impact.

C-Suites and their boards should remember that digital transformation is a key part of the larger focus of a profound business transformation.

While there are still hurdles to overcome along the way, home healthcare could deliver better patient-centered cancer care, providing improved patient outcomes, enhanced quality of life, and reduced strain on resources.